While much attention has been focused lately on breakthrough drugs for treating Alzheimer’s disease, Altoida CEO Marc Jones believes their digital assessment technology will play a crucial role in determining, even before first symptoms appear, whether a case of mild cognitive impairment (MCI) will escalate into Alzheimer’s within a year.
Empowering Primary Care Physicians With Digital Biomarkers For Early Alzheimer’s Detection
Altoida CEO Discusses Company’s Use Of AR, ML To Predict Neurological Disease Progression
Altoida CEO Mark Jones has high hopes that the company’s digital assessment tool will be approved by the FDA to be used along with blood biomarker testing by primary care doctors to help predict Alzheimer’s disease before patients show symptoms.
More from Digital Technologies
More from Leadership
• By
People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.
• By
Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.
• By
Medtech Insight sat down with Anja Streicher, chief marketing officer at Women of Wearables, a global community offering events and education resources to support the femtech industry, to discuss trends in the women's wearables tech market, challenges and innovators pushing the boundaries.